Enteric reabsorption processes and their impact on drug pharmacokinetics

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Physiological Modeling
• Drug Distribution and Elimination

Background:

• Enteric reabsorption, involving drug secretion into and reabsorption from the intestinal lumen, is evidenced by multiple peaks in pharmacokinetic profiles.
• Hepatobiliary drug secretion (enterohepatic reabsorption, EHR) is commonly assumed, but enterogastric reabsorption (EGR) is often overlooked.
• The influence of drug reabsorption on systemic clearance, volume of distribution, and bioavailability remains a topic of extensive discussion.

Purpose of the Study:

• To propose semi-mechanistic pharmacokinetic models for EHR and EGR.
• To compare the impact of EHR and EGR on primary pharmacokinetic parameters.
• To investigate the effects of reabsorption on different drug types based on elimination route and hepatic extraction.

Main Methods:

• Development of semi-mechanistic pharmacokinetic models for EHR and EGR.
• Simulation-based analysis using three drug types: hepatic metabolism-low extraction (A), hepatic metabolism-intermediate/high extraction (B), and renal excretion (C).
• Comparison of the impact of modeled EHR and EGR on key pharmacokinetic parameters.

Main Results:

• Increased EHR significantly reduced clearance for drugs A and B.
• EHR increased bioavailability for drug B and increased volume of distribution for all drug types (A, B, and C).
• Enterogastric reabsorption (EGR) demonstrated a negligible impact on all evaluated pharmacokinetic parameters.

Conclusions:

• Enterohepatic reabsorption plays a significant role in modulating drug pharmacokinetics, affecting clearance, bioavailability, and volume of distribution.
• Enterogastric reabsorption has minimal influence on systemic drug disposition.
• Understanding EHR is crucial for predicting pharmacokinetic variability, drug-drug interactions, and disease state effects.